The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies to detect the presence of heterodimers in the cell, as well as to determine the relationship between the antibody binding to the heterodimer in the cancer cell and the sensitivity of the cell to cancer treatment. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.

Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

The present invention is a new tyrosine derivative described below to inhibit hydrolysis of polysulfide.

The new tyrosine derivative formed according to a chemical formula indicated below, wherein one of a-c is “OH” and the rest are “H”; d is C.sub.nH.sub.2nα, where α is “H” or a “halogen atom,” the halogen atom is preferably “I,” and n is an integer from 1 to 5; and e is (NH).sub.x(CO).sub.yC.sub.zH.sub.2zβ, where x is 1 or 0, y is 1 or 0, z is an integer from 1 to 5, β is “H” or a “halogen atom,”.

##STR00001##

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

In various embodiments, rapid, sensitive detection of molecular hydrogen is achieved by in a detector that divides sample gas into two flows by dividing the sample gas before dampening variation and converting hydrogen to water vapor at two different points. For example, a detector may receive sample gas that includes ambient water vapor and hydrogen, divide the sample gas into a chemical conversion flow and bypass flow, perform a first chemical conversion of hydrogen in the chemical conversion flow to water vapor, alternate between drying the converted chemical conversion flow or the bypass flow to produce a modulated flow, perform a second chemical conversion of hydrogen in the modulated flow to water vapor, measure water vapor in the converted modulated flow to produce a water vapor signal, separate the water vapor signal in the time domain to extract a hydrogen-derived water vapor signal, and output a hydrogen signal based thereon.

A sample heating unit 30 has a space in which an oxidation catalyst is arranged, and heats a sample arranged in the space. A carrier gas introduction unit 40 introduces inert gas containing water vapor as carrier gas into the sample heating unit 30. A detection unit 35 detects carbon dioxide generated by steam reforming reaction of organic carbon in a sample in the sample heating unit 30.

The present invention relates to an in vitro method for the prognosis of survival of a patient suffering from a solid cancer, comprising the quantification of the cell density of CD8+ cells and DC-LAMP+ dendritic cells present in a tumor tissue sample from said patient, wherein a high density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has a favorable prognosis, a high density of CD8+ cells and a low density of DC-LAMP+ dendritic cells indicates that the patient has a poor prognosis, and a low density of CD8+ cells and DC-LAMP+ dendritic cells indicates that the patient has the worst prognosis.

The present disclosure relates to compounds of Formula I, II, or III and compositions of the same, which are reversible off-on or ratiometric fluorescent iron sensors and are useful in live-cell imaging of labile iron ions and their quantification in subcellular compartments, as well as treatment of diseases associated with iron dyshomoestasis.